Cargando…
Neoadjuvant Programmed Cell Death Protein 1 Blockade Combined With Stereotactic Body Radiation Therapy for Stage III(N2) Non-Small Cell Lung Cancer: A Case Series
The addition of radiotherapy in neoadjuvant chemotherapy did not improve event-free or overall survival in resectable non-small cell lung carcinoma (NSCLC). Neoadjuvant immunotherapy produced major pathologic response(MPR) rate of up to 45%. The potential synergy between radiotherapy and immunothera...
Autores principales: | Wang, Zhen, Qiang, Yong, Shen, Qin, Zhu, Xi-Xu, Song, Yong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8936067/ https://www.ncbi.nlm.nih.gov/pubmed/35321437 http://dx.doi.org/10.3389/fonc.2022.779251 |
Ejemplares similares
-
Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy
por: Kumar, Sameera S., et al.
Publicado: (2017) -
Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Cost-Effectiveness Results
por: Bijlani, Akash, et al.
Publicado: (2013) -
Neoadjuvant Chemoradiotherapy for Stage III Non-Small Cell Lung Cancer
por: Sher, David J.
Publicado: (2017) -
Case Report: Aumolertinib as Neoadjuvant Therapy for Patients With Unresectable Stage III Non-Small Cell Lung Cancer With Activated EGFR Mutation: Case Series
por: Feng, Shao, et al.
Publicado: (2022) -
Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer
por: Gallagher, Lindsey, et al.
Publicado: (2023)